Logo image of BSLK

BOLT PROJECTS HOLDINGS INC (BSLK) Stock Fundamental Analysis

NASDAQ:BSLK - Nasdaq - US09769B2060 - Common Stock - Currency: USD

5.9  +0.01 (+0.17%)

Fundamental Rating

1

Overall BSLK gets a fundamental rating of 1 out of 10. We evaluated BSLK against 85 industry peers in the Chemicals industry. BSLK has a bad profitability rating. Also its financial health evaluation is rather negative. BSLK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BSLK had negative earnings in the past year.
BSLK had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BSLK reported negative net income in multiple years.
In the past 5 years BSLK always reported negative operating cash flow.
BSLK Yearly Net Income VS EBIT VS OCF VS FCFBSLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -490.70%, BSLK is doing worse than 95.29% of the companies in the same industry.
Industry RankSector Rank
ROA -490.7%
ROE N/A
ROIC N/A
ROA(3y)-256.36%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSLK Yearly ROA, ROE, ROICBSLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

BSLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSLK Yearly Profit, Operating, Gross MarginsBSLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

BSLK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BSLK remains at a similar level compared to 1 year ago.
Compared to 1 year ago, BSLK has an improved debt to assets ratio.
BSLK Yearly Shares OutstandingBSLK Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
BSLK Yearly Total Debt VS Total AssetsBSLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

BSLK has an Altman-Z score of -62.18. This is a bad value and indicates that BSLK is not financially healthy and even has some risk of bankruptcy.
BSLK has a Altman-Z score of -62.18. This is amonst the worse of the industry: BSLK underperforms 85.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -62.18
ROIC/WACCN/A
WACC6.16%
BSLK Yearly LT Debt VS Equity VS FCFBSLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.28 indicates that BSLK should not have too much problems paying its short term obligations.
With a Current ratio value of 1.28, BSLK is not doing good in the industry: 72.94% of the companies in the same industry are doing better.
A Quick Ratio of 1.02 indicates that BSLK should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.02, BSLK perfoms like the industry average, outperforming 48.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.02
BSLK Yearly Current Assets VS Current LiabilitesBSLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

BSLK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3742.56%.
BSLK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.10%.
EPS 1Y (TTM)-3742.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.83%
Revenue 1Y (TTM)-60.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BSLK Yearly Revenue VS EstimatesBSLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 1M 2M 3M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BSLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BSLK Price Earnings VS Forward Price EarningsBSLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSLK Per share dataBSLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BSLK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT PROJECTS HOLDINGS INC

NASDAQ:BSLK (5/2/2025, 8:00:02 PM)

5.9

+0.01 (+0.17%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners38.83%
Inst Owner Change0.58%
Ins Owners5.64%
Ins Owner Change-5.28%
Market Cap10.15M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-9.4
FCFYN/A
OCF(TTM)-9.39
OCFYN/A
SpS0.79
BVpS-5.01
TBVpS-5.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -490.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-256.36%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1150%
Cap/Sales 1.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.02
Altman-Z -62.18
F-Score4
WACC6.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3742.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-60.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1652.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.75%
OCF growth 3YN/A
OCF growth 5YN/A